Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Roche Makes Lowered, Hostile Bid For Genentech

By Pharmaceutical Processing | January 30, 2009

BASEL, Switzerland (AP) — Swiss pharmaceuticals company Roche Holding AG made a fresh bid to buy U.S.-based Genentech Inc. Friday by offering $86.50 per share — $2.50 less than its previous offer — directly to shareholders. The move by Roche, which already owns 55.8 percent of Genentech, comes after its earlier offer of $89 per share was rejected as too low by the South San Francisco-based company’s board last July. The new offer values the outstanding shares at $42.1 billion, about $1.6 billion less than the previous bid. Genentech shares closed at $84.09 Thursday on the New York Stock Exchange. The stock has traded between $66.80 and $99.14 over the past 52 weeks. Roche said its new offer is aimed directly at shareholders, bypassing the board. “We feel it is now time to give the Genentech minority shareholders the opportunity to decide on our offer,” Roche chairman Franz Humer said in a statement. “Especially in the current market environment the offer provides an opportunity for all public shareholders to achieve liquidity and to receive a fair price for all their shares.” Experts expressed concern that the hostile bid could harm relations at the boardroom level. Analysts at the St. Gallen-based private bank Wegelin spoke of a “worrying gap” between Roche and Genentech executives, saying a successful takeover might results in key people leaving the Californian company out of frustration. Zuercher Kantonalbank said it expects Roche’s takeover attempt to fail. Roche said it intends to retain Genentech’s South San Francisco base as an independent research center if the takeover succeeds.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE